Cost effectiveness of pharmacogenomics: A critical and systematic review

PharmacoEconomics

Volumn 28, Issue 11, 2010, Pages 1001-1013

  Wong, William B ^a   Carlson, Josh J ^a   Thariani, Rahber ^a   Veenstra, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cost effectiveness; Cost utility; Cytochrome P450; Pharmacogenomics

Indexed keywords

ABACAVIR; ALPHA ADDUCIN; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CEFTAZIDIME; CLOZAPINE; CYTOCHROME P450 2C9; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOCETAXEL; DOPAMINE 2 RECEPTOR; ERLOTINIB; GLUCURONOSYLTRANSFERASE 1A1; HLA B5701 ANTIGEN; IRINOTECAN; LEUKOCYTE ANTIGEN; MENADIONE EPOXIDE; ORAL CONTRACEPTIVE AGENT; QUINOLONE; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB; UNCLASSIFIED DRUG; WARFARIN;

BREAST CANCER; CLINICAL PRACTICE; COLON CANCER; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG TARGETING; ECONOMIC EVALUATION; ENTERITIS; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEART ATRIUM FIBRILLATION; HUMAN GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LUNG NON SMALL CELL CANCER; MAJOR DEPRESSION; ORAL CONTRACEPTION; OUTCOME ASSESSMENT; PHARMACOGENOMICS; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TOBACCO DEPENDENCE; VENOUS THROMBOEMBOLISM;

COST-BENEFIT ANALYSIS; GENETIC TESTING; HUMANS; PHARMACOGENETICS; QUALITY-ADJUSTED LIFE YEARS;

EID: 77957995461     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11537410-000000000-00000     Document Type: Review

References (91)

1. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res 2009 Dec; 154(6):277-87
2. Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 2004;22(8):481-93
3. Phillips KA, Van Bebber SL. A systematic review of costeffectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 2004 Dec; 5(8):1139-49
4. Dervieux T, Bala MV. Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics 2006 Dec; 7(8):1175-84
5. Carlson JJ, Henrikson NB, Veenstra DL, et al. Economic analyses of human genetics services: a systematic review. Genet Med 2005 Oct; 7(8):519-23
6. Vegter S, Boersma C, Rozenbaum M, et al. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics 2008;26(7):569-87
7. US National Library of Medicine, National Institutes of Health. PubMed [online]. Available from URL: http://www.pubmed.gov [Accessed 2010 Jul. 19]
8. National Institute for Health and Clinical Excellence. NHS evidence [online]. Available from URL: http://www.nice.org.uk/nhsevidence/[Accessed 2010 Jul. 19]
9. Tufts Medical Centre. Institute for Clinical Research and Health Policy Studies. Center for the Evaluation of Value and Risk in Health [online]. Available from URL: http://www.tufts-nemc.org/cearegistry [Accessed 2010 Jul. 19]
10. Canadian Agency for Drugs and Technologies in Health (CADTH) [online]. Available from URL: http://www.cadth.ca/index.php/en/home [Accessed 2010 Jul. 19]
11. Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 2005
12. Chiou CF, Hay JW, Wallace JF, et al. Development and validation of a grading system for the quality of costeffectiveness studies. Med Care 2003 Jan; 41(1):32-44
13. Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm 2003 Jan-Feb; 9(1):53-61
14. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996 Aug. 3; 313(7052):275-83
15. Centers for Disease Control and Prevention. Public health genomics: genomic translation. ACCE model process for evaluating genetic tests [online]. Available from URL: http://www.cdc.gov/genomics/gtesting/ACCE/index.htm [Accessed 2009 Dec. 9]
16. Kemp LK, Doran CM, Vos T, et al. Cost-effectiveness analysis of genetic screening for the Taq1B polymorphism in the secondary prevention of coronary heart disease. Exp Rev Pharmacoeconomics Outcomes Res 2007;7(2):119-28
17. King CH, Fischler DF, Gerkin RD. Will genetic testing alter the management of disease caused by infectious agents? A cost-effectiveness analysis of gene-testing strategies for prevention of rheumatic fever. Clin Infect Dis 2002 Jun. 1; 34(11):1491-9
18. Tavadia SM, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000 Apr; 42(4):628-32
19. Barrow E, McMahon R, Evans DG, et al. Cost analysis of biomarker testing for mismatch repair deficiency in nodepositive colorectal cancer. Br J Surg 2008 Jul; 95(7):868-75
20. Chou WH, Yan FX, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 2000 Apr; 20(2):246-51
21. Jorgensen AL, Al-Zubiedi S, Zhang JE, et al. Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics 2009 Oct; 19(10):800-12
22. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41(12):913-58
23. Gagne G, Reinharz D, Laflamme N, et al. Hereditary hemochromatosis screening: effect of mutation penetrance and prevalence on cost-effectiveness of testing algorithms. Clin Genet 2007 Jan; 71(1):46-58
24. Anderson K, Jacobson JS, Heitjan DF, et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 2006 Mar. 21; 144(6):397-406
25. Phillips KA, Ackerman MJ, Sakowski J, et al. Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index cases. Heart Rhythm 2005 Dec; 2(12):1294-300
26. Wonderling D, Umans-Eckenhausen MA, Marks D, et al. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in the Netherlands. Semin Vasc Med 2004 Feb; 4(1):97-104
27. Higashi MK, Veenstra DL, del Aguila M, et al. The costeffectiveness of interleukin-1 genetic testing for periodontal disease. J Periodontol 2002 Dec; 73(12):1474-84
28. Marang-van de Mheen PJ, ten Asbroek AH, Bonneux L, et al. Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in the netherlands. Eur Heart J 2002 Dec; 23(24):1922-30
29. Dendukuri N, Khetani K, McIsaac M, et al. Testing for HER2-positive breast cancer: a systematic review and costeffectiveness analysis. CMAJ 2007 May 8; 176(10):1429-34
30. Morelle M, Hasle E, Treilleux I, et al. Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France. Int J Technol Assess Health Care 2006 Summer; 22(3):396-401
31. Auerbach AD, Sanders GD, Hambleton J. Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. Am J Med 2004 Jun. 15; 116(12):816-28
32. Eckman MH, Singh SK, Erban JK, et al. Testing for factor V leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis. Med Decis Making 2002 Mar-Apr; 22(2):108-24
33. Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V leiden: cost-effectiveness analysis. Thromb Haemost 2000 Nov; 84(5):752-7
34. Bushnell CD, Datta SK, Goldstein LB. Cost implications of specialized coagulation testing for acute ischemic stroke. J Stroke Cerebrovasc Dis 2001 Nov-Dec; 10(6):279-83
35. Marchetti M, Quaglini S, Barosi G. Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V leiden and prothrombin G20210A. QJM 2001 Jul; 94(7):365-72
36. Eckman MH, Rosand J, Greenberg SM, et al. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009 Jan 20; 150(2):73-83
37. Gold HT, Hall MJ, Blinder V, et al. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 2009 Sep. 1; 115(17):3858-67
38. Meckley LM, Gudgeon JM, Anderson JL, et al. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 2009;28(1):1-15
39. Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2009 September 1; 2(5):429-36
40. Perlis RH, Patrick A, Smoller JW, et al. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR *D study. Neuropsychopharmacology 2009 Sep; 34(10):2227-36
41. Vegter S, Perna A, Hiddema W, et al. Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. Pharmacogenet Genomics 2009 Sep; 19(9):695-703
42. Carlson JJ, Garrison LP, Ramsey SD, et al. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in nonsmall-cell lung cancer. Value Health 2009 Jan; 12(1):20-7
43. Schackman BR, Scott CA, Walensky RP, et al. The costeffectiveness of HLA-B *5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008 Oct. 1; 22(15):2025-33
44. Smith KJ, Monsef BS, Ragni MV. Should female relatives of factor V leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis. Thromb Haemost 2008 Sep; 100(3):447-52
45. Welton NJ, Johnstone EC, David SP, et al. A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine Tob Res 2008 Jan; 10(1):231-40
46. Lyman GH, Cosler LE, Kuderer NM, et al. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 2007 Mar. 15; 109(6):1011-8
47. Veenstra DL, Harris J, Gibson RL, et al. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet Med 2007 Oct; 9(10):695-704
48. Meckley LM, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genomics 2006 Feb; 16(2):139-47
49. Priest VL, Begg EJ, Gardiner SJ, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 2006;24(8):767-81
50. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 2005 May; 11(5):313-24
51. Perlis RH, Ganz DA, Avorn J, et al. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol 2005 Oct; 25(5):427-34
52. Elkin EB, Weinstein MC, Winer EP, et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a costeffectiveness analysis. J Clin Oncol 2004 Mar. 1; 22(5):854-63
53. Maitland-van der Zee AH, Klungel OH, Stricker BH, et al. Pharmacoeconomic evaluation of testing for angiotensinconverting enzyme genotype before starting beta-hydroxybeta-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics 2004 Jan; 14(1):53-60
54. Leey JA, McCabe S, Koch JA, et al. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation. Am J Geriatr Pharmacother 2009 Aug; 7(4):197-203
55. Heitjan DF, Asch DA, Ray R, et al. Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. Pharmacogenomics J 2008 Dec; 8(6):391-9
56. Obradovic M, Mrhar A, Kos M. Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. Pharmacogenomics 2008 May; 9(5):539-49
57. Costa-Scharplatz M, van Asselt AD, Bachmann LM, et al. Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor. Pharmacogenet Genomics 2007 May; 17(5):359-68
58. Kim SK, Jun. JB, El-Sohemy A, et al. Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in korean patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 2006 Jul; 33(7):1266-74
59. Schalekamp T, Boink GJ, Visser LE, et al. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? Clin Pharmacol Ther 2006 Jun; 79(6):511-20
60. van den Akker-van Marle ME, Gurwitz D, Detmar SB, et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in europe. Pharmacogenomics 2006 Jul; 7(5):783-92
61. Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006 Apr; 10(11):1-110
62. Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005 Oct; 100(10):2239-47
63. Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA B *5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004 Jun; 14(6):335-42
64. Oh KT, Anis AH, Bae SC. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in korea. Rheumatology (Oxford) 2004 Feb; 43(2):156-63
65. Winter J, Walker A, Shapiro D, et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004 Sep. 15; 20(6):593-9
66. You JH, Chan FW, Wong RS, et al. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy: a decision analysis. Thromb Haemost 2004 Sep; 92(3):590-7
67. Lehmann DF, Medicis JJ, Franklin PD. Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of helicobacter pylori infection associated with duodenal ulcer. J Clin Pharmacol 2003 Dec; 43(12):1316-23
68. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002 Dec; 29(12):2507-12
69. Creinin MD, Lisman R, Strickler RC. Screening for factor V leiden mutation before prescribing combination oral contraceptives. Fertil Steril 1999 Oct; 72(4):646-51
70. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009 Feb. 19; 360(8):753-64
71. Garcia DA. Warfarin and pharmacogenomic testing: the case for restraint. Clin Pharmacol Ther 2008 Sep; 84(3):303-5
72. Kangelaris KN, Bent S, Nussbaum RL, et al. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med 2009 May; 24(5):656-64
73. Rudnicki M, Mayer G. Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease. Pharmacogenomics 2009 Mar; 10(3):463-76
74. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP working group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med 2009 Jan; 11(1):15-20
75. Munafo MR, Timpson NJ, David SP, et al. Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a meta-analysis and new data. Nicotine Tob Res 2009 Jan; 11(1):64-76
76. Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA 2009 Jun. 17; 301(23):2472-85
77. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP working group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med 2009 Jan; 11(1):66-73
78. Hughes AR, Spreen WR, Mosteller M, et al. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J 2008 Dec; 8(6):365-74
79. Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical Oncology/College of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007 Jan 1; 25(1):118-45
80. Davis BR, Arnett DK, Boerwinkle E, et al. Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the genetics of hypertension-associated treatment study. Pharmacogenomics J 2007 Apr; 7(2):112-22
81. Ballana E, Mercader JM, Fischel-Ghodsian N, et al. MRPS18CP2 alleles and DEFA3 absence as putative chromosome 8p23.1 modifiers of hearing loss due to mtDNA mutation A1555G in the 12S rRNA gene. BMC Med Genet 2007 Dec. 21; 8:81
82. Zhao F, Wang J, Yang Y, et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitorbased triple therapy for helicobacter pylori eradication: a meta-analysis. Helicobacter 2008 Dec; 13(6):532-41
83. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 2009 Sep. 3; 361(10):1018-20
84. Lin E, Chen PS, Chang HH, et al. Interaction of serotoninrelated genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009 Oct. 1; 33(7):1167-72
85. Ikeda M, Yamanouchi Y, Kinoshita Y, et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008 Oct; 9(10):1437-43
86. de Leon J, Arranz MJ, Ruano G. Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med 2008 Dec; 28(4):599-617
87. National Comprehensive Cancer Network (NCCN). Breast cancer clinical guidelines [online]. Available from URL: http://www.nccn.org/professionals/ physician-gls/PDF/breast.pdf [Accessed 2010 Aug. 11]
88. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rockville (MD): Department of Health and Human Services, 2009 Dec. 1 [online]. Available from URL: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL. pdf [Accessed 2010 Aug. 11]
89. Gerhard T, Gong Y, Beitelshees AL, et al. Association between CV outcomes diuretic use and the alpha-adducin gene: results from the INternational VErapamil SR-trandolapril STudy (INVEST) [abstract]. Circulation 2005;112 Suppl. 2:608
90. Gerhard T, Beitelshees AL, Johnson JA. Re: Meckley LM, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis [letter]. Pharmacogenet Genom 2006;16:139-147.
91. Pharmacogenet Genomics 2006 Aug; 16(8):613